- Clinical trials of Clene’s lead candidate CNM-Au8(R) have shown notable success in crossing the blood-brain barrier and enhancing the brain’s bioenergetic metabolites, essentially “reversing the clock” on what would be considered healthy aging
- CNM-Au8 has shown promise in clinical trials for both ALS and MS, including improvements in survival rates and clinical function
- Clene was recently featured in an interview of CEO Rob Etherington on ‘First in Human’ podcast
In a significant advancement for the treatment of neurodegenerative diseases, Clene (NASDAQ: CLNN) has innovated CNM-Au8, an oral nanotherapeutic designed to revitalize the brain’s mitochondrial function. The potential of this drug to treat multiple neurological diseases was highlighted during the latest episode of the “First In Human” podcast, hosted by Vial’s Executive Vice President of CRO Operations, Rich McCormick, featuring Clene’s CEO, Rob Etherington (https://nnw.fm/I07Wm).
Etherington, who has nearly 32 years of experience in pharmaceutical drug development, discussed the journey of CNM-Au8 from its conception to the promising results of clinical trials. These trials have demonstrated the drug’s potential to significantly enhance neurological functions, offering new hope to individuals battling Amyotrophic Lateral Sclerosis (“ALS”) and Multiple Sclerosis (“MS”).
The inspiration for CNM-Au8 comes from the therapeutic potential of elemental metals, a concept understood in both Western and Eastern medicine traditions. Clene’s approach, which leverages nanotechnology, focuses on improving mitochondrial function to support the complex electrical activity necessary for movement, cognitive function, and more. Etherington highlighted that CNM-Au8 is tailored to address the central nervous system’s needs, targeting diseases like ALS and MS.
“For decades…the idea of a therapeutic elemental metal having some medicinal efficacy has been well understood. We at Clene had the idea to combine this with the mechanism of a nanotherapeutic, providing, at the atomic level, the ability to drive energy into the failing mitochondria that powers your and my brain,” Etherington said. “We had the idea to do that with a catalytically active nanotherapeutic suspension, which the patients drink daily.”
Clinical trials of CNM-Au8 have shown notable success in crossing the blood-brain barrier and enhancing the brain’s bioenergetic metabolites, essentially “reversing the clock” on what would be considered healthy aging. This breakthrough has the potential to significantly improve survival and quality of life for patients with neurodegenerative diseases, offering improvements in movement, speech, and overall function.
One of the key differences of CNM-Au8 is its oral consumption method, providing an easily accessible treatment option for patients. Its strong safety profile, without a single reported serious adverse event related to the drug, positions CNM-Au8 as a revolutionary treatment that can be administered alongside standard of care.
Clene’s commitment to addressing neurodegenerative diseases aligns with the urgent need for therapeutic breakthroughs in this field. The World Health Organization has predicted that neurodegenerative disease will become the second most prevalent cause of death within the next 20 years, making innovations like CNM-Au8 critical.
The development of CNM-Au8 has not been without challenges, including the complexity of creating a nanotherapeutic with medicinal efficacy and navigating regulatory pathways. Despite these hurdles, Clene has emerged as a leader in the field, with CNM-Au8 showing promise in clinical trials for both ALS and MS, including improvements in survival rates and clinical function.
Etherington also highlighted Clene’s collaborative efforts, including partnerships with academic centers of excellence and a significant grant from the National Institutes of Health. These collaborations have been instrumental in advancing the development of CNM-Au8 and understanding its mechanisms.
Looking ahead, Clene Inc. aims to transform healthcare for individuals with neurodegenerative diseases through CNM-Au8. The company is working towards regulatory approvals to bring this groundbreaking treatment to market. With its potential to improve mitochondrial function and enhance patient outcomes, CNM-Au8 represents a pioneering approach to treating neurodegenerative diseases.
To listen to the full podcast, visit https://nnw.fm/NHwwl.
For more information, visit the company’s website at www.Clene.com.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is powered by IBN
